Antisense nucleic acids
AssigneesNippon Shinyaku Co., Ltd., National Center of Neurology and Psychiatry
InventorsTatsushi Wakayama, Haruna Seo, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
Life of this patent
Estimating the term…
Abstract
Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.
Claims9
An antisense oligomer of 30-35 nucleobases, or a pharmaceutically acceptable salt or hydrate thereof, wherein the antisense oligomer is a morpholino oligomer, a peptide nucleic acid (PNA), or an oligonucleotide comprising at least one nucleotide having:
- (i) a modified sugar moiety, wherein the 2′-OH group of a ribose is replaced by any one selected from the group consisting of R, R′OR, SH, SR, NH2, NHR, NR2, N3, CN, F, Cl, Br and I (wherein R is an alkyl or an aryl and R′ is an alkylene), or
- (ii) a modified phosphate-binding region selected from the group consisting of a phosphorothioate bond, a phosphorodithioate bond, an alkylphosphonate bond, a phosphoramidate bond, and a boranophosphate bond,
- and wherein the sequence of nucleobases of the antisense oligomer comprises, or consists of, SEQ ID NO:
- 1 or SEQ ID NO:
- 2.
A method for treatment of muscular dystrophy, which comprises intravenously administering to a patient with muscular dystrophy an antisense oligomer of 25-35 nucleobases, or a pharmaceutically acceptable salt or hydrate thereof, wherein the antisense oligomer is:
- (a) an antisense oligomer comprising the nucleobase sequence of SEQ ID NO:
- 1 or SEQ ID NO:
- 2;
- or
- (b) an antisense oligomer, the nucleobase sequence of which consists of a nucleobase sequence that differs from the nucleobase sequence of SEQ ID NO:
- 1 or SEQ ID NO:
- 2 by no more than 5 nucleobases, wherein each difference independently may be a deletion, a substitution, an insertion, or an addition of a nucleobase, wherein the antisense oligomer has an activity to cause skipping of the 51st exon of a human dystrophin gene;
- wherein the antisense oligomer is a morpholino oligomer, a peptide nucleic acid (PNA), or an oligonucleotide, and wherein the patient with muscular dystrophy has a dystrophin frame shift mutation for which the reading frame can be restored by skipping of exon 51.
Dependencies are inferred from the claim text.